欢迎来到课桌文档! | 帮助中心 课桌文档-建筑工程资料库
课桌文档
全部分类
  • 党建之窗>
  • 感悟体会>
  • 百家争鸣>
  • 教育整顿>
  • 文笔提升>
  • 热门分类>
  • 计划总结>
  • 致辞演讲>
  • 在线阅读>
  • ImageVerifierCode 换一换
    首页 课桌文档 > 资源分类 > PPT文档下载  

    探索抗生素的本质(英文PPT)Probing Nature for Antibiotics.ppt

    • 资源ID:875530       资源大小:4.70MB        全文页数:91页
    • 资源格式: PPT        下载积分:10金币
    快捷下载 游客一键下载
    会员登录下载
    三方登录下载: 微信开放平台登录 QQ登录  
    下载资源需要10金币
    邮箱/手机:
    温馨提示:
    用户名和密码都是您填写的邮箱或者手机号,方便查询和重复下载(系统自动生成)
    支付方式: 支付宝    微信支付   
    验证码:   换一换

    加入VIP免费专享
     
    账号:
    密码:
    验证码:   换一换
      忘记密码?
        
    友情提示
    2、PDF文件下载后,可能会被浏览器默认打开,此种情况可以点击浏览器菜单,保存网页到桌面,就可以正常下载了。
    3、本站不支持迅雷下载,请使用电脑自带的IE浏览器,或者360浏览器、谷歌浏览器下载即可。
    4、本站资源下载后的文档和图纸-无水印,预览文档经过压缩,下载后原文更清晰。
    5、试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓。

    探索抗生素的本质(英文PPT)Probing Nature for Antibiotics.ppt

    Probing Nature for Antibiotics,Struggle for living,www.photos-screensaver-,www.creswell-crags.org.uk,“History of humankind can be regarded from a medicinal point of view as a struggle against infectious diseases”,Yoneyama,H.,Katsumata,R.,Biosci.Biotechnol.Biochem.,2006,70,1060,Survival against infectious diseases,dodd.cmcvellore.ac.in,What are antibiotics?,Molecules that stop the microbial growth(both bacteria and fungi)or kill them outright,Walsh,C.,Antibiotics Actions origins and Resistance,2003,4,How do the antibiotics act against bacteria?,Walsh,C.,Antibiotics Actions origins and Resistance,2003,Cell Wall Biosynthesis-lactams,Cyclosporins,Glycopeptides,How do the antibiotics act against bacteria?,Walsh,C.,Antibiotics Actions origins and Resistance,2003,19,Protein BiosynthesisAminoglycosides,Macrolides,Tetracyclines,Oxazolidinones,How do the antibiotics act against bacteria?,Walsh,C.,Antibiotics Actions origins and Resistance,2003,19 publications.nigms.nih.gov,DNA BiosynthesisQuinolones,RNA BiosynthesisRifampicin,How do the antibiotics act against bacteria?,Walsh,C.,Antibiotics Actions origins and Resistance,2003,19,Metabolic pathways Folic Acid MetabolismTrimethoprim,SulfonamidesFatty Acid BiosynthesisTriclosan,Isoniazid,Ethionamide,Why do we need more antibiotics?,-Developing antimicrobial resistanceBacterial species Common types of Antimicrobial Types of Infections ResistanceStreptococcus pneumoniae-lactams,cephalosporins,macrolidesOtitis media,pneumonia,Tetracyclines sinusitis,meningitis Staphylococcus aureusCommunity-associated Meticillin,cephalosporins,macrolides Skin,soft tissue,sepsis pneumoniaHealthcare-associated Meticillin,cephalosporins,quinolones,Endocarditis,pneumonia,aminoglycosides,macrolidessepsisEnterococcus spp.Ampicillin,vancomycin,aminoglycosides Sepsis,urinary tract,Furuya,E.Y.,Lowy,F.D.,Nature,2006,4,36,What should be targeted?,The compounds with,Novel structuresNew modes of action,Fernandes,P.,Nature Biotechnology,2006,24,1497,Where do the antibiotics come from?,NATURE,Where do the antibiotics come from?,NATURE,NP,SS,TS,Where do the antibiotics come from?,NATURE,NP,SS,TS,Helps in designing the molecules,Natural products as antibiotics,Naturally occurring compounds that are end products of secondary metabolism.Mostly extracted from plants,marine organisms,or microorganisms.,Singh,S.B.,Barrett,J.F.,Biochemical Pharmacology,2006,71,1006,Natural products as antibiotics,Naturally occurring compounds that are end products of secondary metabolism.Mostly extracted from plants,marine organisms,or microorganisms.Eg:,Singh,S.B.,Barrett,J.F.,Biochemical Pharmacology,2006,71,1006Pal,S.,Tetrahedron,2006,62,3171,Erythromycin,Isolation-Streptomyces erythreus in 1952Uses-Respiratory tract diseases,genital infectionsMOA-Inhibition of protein synthesis,Antibiotics which are semi-synthesized,Synthetically modified chemical compounds which are originated from natural products.,Walsh,C.,Antibiotics Actions origins and Resistance,2003,4,Erythromycin is,Acid unstable,Pal,S.,Tetrahedron,2006,62,3171,Antibiotics which are semi-synthesized,Clarithromycin,Azithromycin,HMR3647,TE802,Pal,S.,Tetrahedron,2006,62,3171,Antibiotics which are totally from synthesis,Totally synthesized molecules which are potent as antibiotics.Three main types.1.Sulfa drugs 2.Quinolones 3.Oxazolidinones,Singh,S.B.,Barrett,J.F.,Biochemical Pharmacology,2006,71,1006,Antibiotics which are totally from synthesis,Sulfa drugs(Sulphonamides),Uses-Urinary tract infections,pneumonia etc.MOA-Inhibition of folate synthesis,Harold,P.L.,OGrady,F.W.,Antibiotic and Chemotherapy,1992,6,268-272,Sulfamethoxazole,Singh,S.B.,Barrett,J.F.,Biochemical Pharmacology,2006,71,1006,Antibiotics which are totally from synthesis,Sulfa drugs(Sulphonamides)Naturally occurring,Uses-Urinary tract infections,pneumonia etc.MOA-Inhibition of folic acid biosynthesis,Harold,P.L.,OGrady,F.W.,Antibiotic and Chemotherapy,1992,6,268-272,Sulfamethoxazole,Singh,S.B.,Barrett,J.F.,Biochemical Pharmacology,2006,71,1006Walsh,C.,Antibiotics Actions origins and Resistance,2003,80-82,p-aminobenzoic acid,Antibiotics which are totally from synthesis,Quinolones,Ciprofloxacin,Uses-Urinary tract infections,Lower respiratory infections,Gastrointestinal infectionsMOA-Inhibition of DNA synthesis,Singh,S.B.,Barrett,J.F.,Biochemical Pharmacology,2006,71,1006,Antibiotics which are totally from synthesis,Quinolones Naturally occurring,Ciprofloxacin,Uses-Urinary tract infections,Lower respiratory infections,Gastrointestinal infectionsMOA-Inhibition of DNA synthesis,Singh,S.B.,Barrett,J.F.,Biochemical Pharmacology,2006,71,1006Kunze,B.,Hofle,G.,Reichenbach,H.,J.Antibiotics,1987,40,258,Aurachin C,Aurachin D,Antibiotics which are totally from synthesis,Oxazolidinones,Ford,C.W.,Zurenko,G.E.,Barbachyn,M.R.,Current Drug Targets-Infectious Disorders,2001,1,181,Linezolid,Uses-Soft tissue infections,skin infections,Tuberculosis etc.MOA-Inhibition of protein synthesis,Antibiotics which are totally from synthesis,Oxazolidinones Naturally occurring,Ford,C.W.,Zurenko,G.E.,Barbachyn,M.R.,Current Drug Targets-Infectious Disorders,2001,1,181Zappia,G.,et al.,Mini-Reviews in Medicinal Chemistry,2007,7,389,Linezolid,Uses-Soft tissue infections,skin infections,Tuberculosis etc.MOA-Inhibition of protein synthesis,(-)-Cytoxazone,(+)-Sreptazolin,Sources of antibacterial drugs from 1981 to 2002,Newman,D.J.,Cragg,G.M.,Snader,K.M.,J.Nat.Prod.,2003,66,1022,Ways of probing nature for antibiotics,Ways of probing nature for antibiotics,New antibiotics New architectural scaffolds,Approach A,Conventional way of NP discovery,Singh,S.B.,Barrett,J.F.,Biochemical Pharmacology,2006,71,1006www.spc.int,www.oceanexplorer.noaa.gov,Extraction to the solvents,Isolation and Structure Elucidation,Natural materials,Bioassay guided fractionation,Approach A,Conventional way of NP discoveryWhy isnt it successful?Problems associated with the growth or the availability of the sourceReplication of the hitsDo not distinguish novel from oldMostly miss the novel compounds due to the lack of sensitivityNo hints about MOACannot reveal potency at screening stage,Singh,S.B.,Barrett,J.F.,Biochemical Pharmacology,2006,71,1006Clardy,J.,Fischbach,M.A.,Walsh,C.,Nat.Rev.Biotechnol.,2006,24,1541,Approach A,What are the new strategies to explore nature for NPs,Molecular Biology based Techniques,Novel culturing techniques,Heterologous expression of biosynthetic genes&Metagenomics,Genomics and Combinatorial biosynthesis,Precursor directed biosynthesis&Mutasynthesis,Differential sensitivity screening approach,Singh,S.B.,Barrett,J.F.,Biochemical Pharmacology,2006,71,1006Clardy,J.,Fischbach,M.A.,Walsh,C.,Nat.Rev.Biotechnol.,2006,24,1541Donadio,S.,Chemistry&Biology,2006,13,560,Approach A,What are the new strategies to explore nature for NPs,Molecular Biology based Techniques,Novel culturing techniques,Heterologous expression of biosynthetic genes&Metagenomics,Genomics and Combinatorial biosynthesis,Precursor directed biosynthesis&Mutasynthesis,Differential sensitivity screening approach,Singh,S.B.,Barrett,J.F.,Biochemical Pharmacology,2006,71,1006Clardy,J.,Fischbach,M.A.,Walsh,C.,Nat.Rev.Biotechnol.,2006,24,1541Donadio,S.,Chemistry&Biology,2006,13,560,Approach A,Extraction to the Solvents,Producing organismsfound in nature,Pathogen,Precursor Directed Biosynthesis&Mutasynthesis,Wild type,Mutant type,Approach A,Precursor Directed Biosynthesis&Mutasynthesis,Natural Biosynthetic pathway,Kennedy,J.,Nat.Prod.Rep.,2008,25,25Weist,S.,Sssmuth,R.D.,Appl.Microbiol.Biotechnol.,2005,68,141,Wild type,Approach A,Precursor Directed Biosynthesis and Mutasynthesis,Precursor-Directed Biosynthesis,Wild type,Kennedy,J.,Nat.Prod.Rep.,2008,25,25Weist,S.,Sssmuth,R.D.,Appl.Microbiol.Biotechnol.,2005,68,141,Approach A,Precursor Directed Biosynthesis and Mutasynthesis,Mutasynthesis,Mutant,Mutasynthon,Kennedy,J.,Nat.Prod.Rep.,2008,25,25Weist,S.,Sssmuth,R.D.,Appl.Microbiol.Biotechnol.,2005,68,141,Approach A,Mutasynthesis,Pojer,F.,Li,S.M.,Heide,L.,Microbiology,2002,148,3901Galm,U.,et al,Chemistry&Biology,2004,11,173Weist,S.,Sssmuth,R.D.,Appl.Microbiol.Biotechnol.,2005,68,141,Ring A Ring B Ring CNovobiocin(Albamycin),Ring A Ring B Ring CClorobiocin,Approach A,Mutasynthesis,CloQ-mutants,Pojer,F.,Li,S.M.,Heide,L.,Microbiology,2002,148,3901Galm,U.,et al,Chemistry&Biology,2004,11,173Eustquio,A.S.,et al,Arch.Microbiol.,2003,180,25,Approach A,Mutasynthesis,Galm,U.,et al,Chemistry&Biology,2004,11,173 Pojer,F.,Li,S.M.,Heide,L.,Microbiology,2002,148,3901,CloQ-mutant,Clorobiocin,Approach A,Mutasynthesis,CloQ-mutant,Clorobiocin,Galm,U.,et al,Chemistry&Biology,2004,11,173 Pojer,F.,Li,S.M.,Heide,L.,Microbiology,2002,148,3901,Approach A,Mutasynthesis,CloQ-mutant,Analogs of Clorobiocin,Galm,U.,et al,Chemistry&Biology,2004,11,173 Galm,U.,et al,Antimicrob.Agents Chemother.,2004,48,1307 Pojer,F.,Li,S.M.,Heide,L.,Microbiology,2002,148,3901,Approach A,What are the new strategies to explore nature for NPs,Molecular Biology based Techniques,Novel culturing techniques,Heterologous expression of biosynthetic genes&Metagenomics,Genomics and Combinatorial biosynthesis,Precursor directed biosynthesis&Mutasynthesis,Differential sensitivity screening approach,Singh,S.B.,Barrett,J.F.,Biochemical Pharmacology,2006,71,1006Clardy,J.,Fischbach,M.A.,Walsh,C.,Nat.Rev.Biotechnol.,2006,24,1541Donadio,S.,Chemistry&Biology,2006,13,560,Approach A,Differential sensitivity screening approach,Extraction to the solvents,Couzin,J.,Nature,2006,314,34,ForsythR.A.,Molecular Biology,2002,43,1387 Wang,J.,et al,Antimicrob.Agents Chemother.,2006,50,519,Producingorganism from nature,Disabled type,Wild type,Increased sensitivity,Low,Normal,Pathogen,Expression of certain protein/s,Target the pathway,Approach A,Differential sensitivity screening approach,Fatty Acid Biosynthesis A good target,FAB Type I-In mammals,FAB Type II-In bacteria,Campbell,J.W.,Cronan,J.E.Jr.,Annu.Rev.Microbiol.,2001,55,305,Biosynthesis of Saturated Fatty Acids,Campbell,J.W.,Cronan,J.E.Jr.,Annu.Rev.Microbiol.,2001,55,305,Biosynthesis of Saturated Fatty Acids,Campbell,J.W.,Cronan,J.E.Jr.,Annu.Rev.Microbiol.,2001,55,305,Biosynthesis of Saturated Fatty Acids,Campbell,J.W.,Cronan,J.E.Jr.,Annu.Rev.Microbiol.,2001,55,305,Singh,S.B.,et al,J.Am.Chem.Soc.,2006,128,11916Forsyth,R.A.,Molecular Biology,2002,43,1387 Wang,J.,et al,Antimicrob.Agents Chemother.,2006,50,519,Approach A,RNA-mediated gene silencing technique,Differential sensitivity screening approach,Reduced or No FabF expression,5 AUGGCCUGGACUUCA33 UACCGGACCTGTTGU 5,ds RNA,Degradation of fabF mRNA or inhibition of translation,In Prokaryotes-,Higher sensitivity towards FabF inhibitors,Singh,S.B.,et al,J.Am.Chem.Soc.,2006,128,11916Forsyth,R.A.,Molecular Biology,2002,43,1387 Wang,J.,et al,Antimicrob.Agents Chemother.,2006,50,519,RNA-mediated gene silencing technique,Differential sensitivity screening approach,Approach A,Approach A,Differential sensitivity screening approach,Results-RNA-mediated gene silencing technique,Wild typefabF Anti-sense,Wang,J.,et al,Nature,2006,441,358,Inhibitor(g),Approach A,Differential sensitivity screening approach,Results-RNA-mediated gene silencing technique,Wild typefabF Anti-sense,Wild typefabF Anti-sense,200 times more potent than Cerulenin,Wang,J.,et al,Nature,2006,441,358Price,A.C.,et al,The Journal of Biological Chemistry,2001,276,6551Heath,R.J.,White,S.W.,Rock,C.O.,Progress in Lipid Research,2001,40,467,Inhibitor(g),Approach A,Differential sensitivity screening approach,Platensimycinfrom a strain of Streptomyces platensis,Singh,S.B.,et al,J.Am.Chem.Soc.,2006,128,11916,Discovery of Platensimycin,Approach A,Differential sensitivity screening approach,Potency of Platensimycin,Organism and genotype Platensimycin LinezolidAntibacterial activity(MIC,g/ml)S.aureus(MSSA)0.5 4 S.aureus(MRSA)0.5 2 S.aureus(MRSA,macrolideR)0.5 2 S.aureus(MRSA,linezolidR)1 32 Enterococcus faecium(VRE)0.1 2,MIC Concentration of inhibitor used to result no visible growth of the pathogens,Wang,J.,et al,Nature,2006,441,358,Toxicity(g/ml)HeLa MTT(IC50)1,000 100,IC50 Concentration of the inhibitor used to kill 50%population of the living cells,Cell-free gel-elongation assay,Wang,J.,et al,Nature,2006,441,358,Malonyl-ACP,C4:1(2)-ACP,C4:0-ACP,6C-ACP,Approach A,Differential sensitivity screening approach,High FabF selectivity,Heath,R.J.,Nat.Prod.Rep.,2002,19,581,Ways of probing nature for antibiotics,New antibiotics New architectural scaffolds,Approach B,Singh,S.B.,Barrett,J.F.,Biochemical Pharmacology,2006,71,1006Clardy,J.,Fischbach,M.A.,Walsh,C.,Nat.Rev.Biotechnol.,2006,24,1541,Generating Nature Mimics,Biosynthetic pathway,Designing theoretical chemical space that fits the active site or docking the database structures,Translate to a real structure by synthesis,Enzyme purification&3D structural determination,Approach B,Hutton,C.A.,Perugini,M.A.,Gerrard,J.A.,Mol.Biosyst.,2007,3,458Hutton,C.A.,Southwood,T.J.,Turner,J.J.,Mini-Reviews in Medicinal Chemistry,2003,3,115,Essential for the bacterial growth Does not exist in mammals,Generating Nature Mimics,Biosynthesis of lysine A good target,isoleucine,threonine,methionine,Hutton,C.A.,Perugini,M.A.,Gerrard,J.A.,Mol.Biosyst.,2007,3,458Hutton,C.A.,Southwood,T.J.,Turner,J.J.,Mini-Reviews in Medicinal Chemistry,2003,3,115,Biosynthesis of lysine,Hutton,C.A.,Perugini,M.A.,Gerrard,J.A.,Mol.Biosyst.,2007,3,458Hutton,C.A.,Southwood,T.J.,Turner,J.J.,Mini-Reviews in Medicinal Chemistry,2003,3,115,Biosynthesis of lysine,Approach B,Generating Nature Mimics,Hutton,C.A.,Perugini,M.A.,Gerrard,J.A.,Mol.Biosyst.,2007,3,458Hutton,C.A.,Southwood,T.J.,Turner,J.J.,Mini-Reviews in Medicinal Chemistry,2003,3,115,Proposed mechanism,Approach B,Generating Nature Mimics,Supportive data,Faehnle,C.R.,Coq,J.L.,Liu,X.,Viola,R.E.,Journal of Biological Chemistry,2006,281,31031 Cox,R.J.,Gibson,J.S.,Martn,M.B.M.,ChemBioChem,2002,3,874Hutton,C.A.,Southwood,T.J.,Turner,J.J.,Mini-Reviews in Medicinal Chemistry,2003,3,115,Approach B,Generating Nature Mimics,Cox,R.J.,Gibson,J.S.,Martn,M.B.M.,Chem.Commun.,2001,1710Cox,R.J.,Gibson,J.S.,Hadfield,A.T.,ChemBioChem,2005,6,2255Cox,R.J.,Gibson,J.S.,Martn,M.B.M.,ChemBioChem,2002,3,874,Inhibitors of lysine biosynthesis,Approach B,Generating Nature Mimics,Cox,R.J.,Gibson,J.S.,Martn,M.B.M.,Chem.Commun.,2001,1710Cox,R.J.,Gibson,J.S.,Hadfield,A.T.,ChemBioChem,2005,6,2255Cox,R.J.,Gibson,J.S.,Martn,M.B.M.,ChemBioChem,2002,3,874,Inhibitors of lysine biosynthesis,Approach B,Generating Nature Mimics,Cox,R.J.,Gibson,J.S.,Martn,M.B.M.,ChemBioChem,2002,3,874Cox,R.J.,Gibson,J.S.,Hadfield,A.T.,ChemBioChem,2005,6,2255,Reverse Biosynthesis,In vitro assays,Approach B,Cox,R.J.,Gibson,J.S.,Martn,M.B.M.,ChemBioChem,2002,3,874Blanco,J.,Moore,R.A.,Viola,R.E.,PNAS,2003,100,12613Han,S.,Moore,R.A.,Viola,R.E.,Synlett,2003,6,845,Generating Nature Mimics,KI(ASA)KI(Phosphate),Direct assay,Competitive assays,Approach B,Generating Nature Mimics,Direct assay,Cox,R.J.,Gibson,J.S.,Martn,M.B.M.,ChemBioChem,2002,3,874Blanco,J.,Moore

    注意事项

    本文(探索抗生素的本质(英文PPT)Probing Nature for Antibiotics.ppt)为本站会员(夺命阿水)主动上传,课桌文档仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知课桌文档(点击联系客服),我们立即给予删除!

    温馨提示:如果因为网速或其他原因下载失败请重新下载,重复下载不扣分。




    备案号:宁ICP备20000045号-1

    经营许可证:宁B2-20210002

    宁公网安备 64010402000986号

    课桌文档
    收起
    展开